View all SOBO CME

Share a PER® activity with your colleagues or friends. Connect with the PER® social network.

Accreditation/ Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 24.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


PER Pulse™ Recap
Three PER Pulse™ Recaps summarizing highlights from the 13th Annual School of Breast Oncology® online activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Astellas, Celgene Corporation, Eisai Inc., Genentech, Lilly, Novartis Pharmaceuticals Corporation, and PUMA Biotechnology.

For further information concerning Lilly grant funding visit

13th Annual School of Breast Oncology® Online

Release Date: January 29, 2016
Expiration Date: January 29, 2017
Media: Internet - based

Repurposing Statement

If you previously attended and received credit for the live CME-certified conference titled 13th Annual School of Breast Oncology®, which was held November 5-7, 2015, in Atlanta, GA, please note that you will not receive credit for completing this activity. Participants who take part in an identical activity, even in order to validate learning or to clarify specific topics, cannot claim, nor will Physicians' Education Resource®, LLC, (PER®) award, duplicate credit for the activity.

Activity Overview

Over the past decade, an increasing number of oncologists have concentrated their practices on breast cancer. In order to advance patient care, the School of Breast Oncology® was developed. This curriculum-based program focuses exclusively on breast cancer clinical management, with a comprehensive review of data on the most important aspects of breast cancer biology, diagnostics, prevention, and treatment. This online activity captures all of the lectures presented at the live 2015 School of Breast Oncology®, organized in a convenient modular format, and summarizes the existing data for each topic with an emphasis on the evidence-based foundations for optimal, individualized decision making in the clinic.

CME Activity Table of Contents

  • Module 1: Breast Carcinogenesis & Management of High-Risk Disease
  • Module 2: Breast Imaging
  • Module 3: Breast Surgery
  • Module 4: Breast Radiation Therapy
  • Module 5: Adjuvant/Neoadjuvant Chemotherapy and Endocrine Therapy
  • Module 6: Treatment of HER2-Positive Disease
  • Module 7: Systemic Treatment of Advanced/Metastatic Disease
  • Module 8: Organ-Targeted Treatment of Metastatic Disease
  • Module 9: Toxicity Management and Survivorship Considerations

Instructions For This Activity & Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, "educational content/video" will be available for your reference.
  • In order to receive a CME certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME certificate upon completion of these steps.

Target Audience

This educational program is directed toward medical oncologists, fellows, surgical oncologists, and radiation oncologists who treat patients with breast cancer.

Educational Objectives

At the conclusion of this activity, you should be better prepared to:
  • Discuss breast carcinogenesis, the impact of germline mutations and breast cancer biology on patient management, and strategies for breast cancer risk reduction
  • Review advances in breast cancer imaging and early detection, including mammography, ultrasound, MRI, and PET scanning
  • Incorporate current guidelines and recent data on local therapy, including new strategies for surgical and radiation therapy, into the treatment of patients with breast cancer
  • Integrate biomarkers, molecular assays, and other risk assessment tools in treatment decision making for breast cancer, when appropriate
  • Incorporate systemic therapies for breast cancer (including endocrine, cytotoxic, targeted, and bone-modifying agents) into individualized treatment plans for patients based upon an evaluation of efficacy and safety, as well as patient characteristics and tumor subtype
  • Evaluate emerging clinical data regarding new agents and evolving strategies for the treatment of breast cancer, and apply clinical trial data appropriately in order to optimize the outcome of individual patients
  • Utilize optimal strategies for preventing and treating breast cancer therapy–related toxicity
  • Select eligible patients with breast cancer for promising clinical trials

Program Director

Joyce O'Shaughnessy, MD
Co-Director, Breast Cancer Research
Baylor Charles A. Sammons Cancer Center
Texas Oncology
The US Oncology Network
Dallas, TX

Curriculum Development Committee

William J. Gradishar, MD, FASCO, FACP
Betsy Bramsen Professor of Breast Oncology
Director, Maggie Daley Center for Women's Cancer Care
Robert H. Lurie Comprehensive Cancer Center of Feinberg School of Medicine
Northwestern University
Chicago, IL

Frankie Ann Holmes, MD, FACP
Associate Director, Breast Oncology Research
Texas Oncology
Houston, TX

Eleftherios Mamounas, MD, MPH, FACS
Medical Director
Comprehensive Breast Program
UF Health Cancer Center -- Orlando Health
Orlando, FL

Anne Moore, MD
Medical Director, Weill Cornell Breast Center
Weill Cornell Medical College
New York, NY

Lori J. Pierce, MD, FASTRO
Professor of Radiation Oncology
University of Michigan School of Medicine
Vice Provost for Academic and Faculty Affairs
University of Michigan
Ann Arbor, MI

Hope S. Rugo, MD
Professor of Medicine
Director, Breast Oncology and Clinical Trials Education
University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
San Francisco, CA


Carey K. Anders, MD
Assistant Professor of Medicine
Division of Hematology Oncology
University of North Carolina at Chapel Hill
Lineberger Comprehensive Cancer Center
Chapel Hill, NC

Douglas W. Arthur, MD
Professor and Vice-Chairman
Natalie N. and John R. Congdon, Sr. Endowed Chair of Cancer Research
Department of Radiation Oncology
Virginia Commonwealth University School of Medicine
Massey Cancer Center
Richmond, VA

David M. Euhus, MD, FACS
Professor (PAR) of Surgery
Chief, Breast Surgery Section
Division of Surgical Oncology
Johns Hopkins Hospital
Baltimore, MD

Carol Fabian, MD
Morris Family Endowed Chair in Cancer Prevention
Director, Breast Cancer Prevention and Survivorship Centers
Professor of Medicine
Division of Clinical Oncology
The University of Kansas Medical Center
Westwood, KS

Karin Hahn MD, MSc, MPH
Senior Medical Director (Oncology)
Associate Professor, Dept. of Oncology
University of Western Ontario
London Regional Cancer Program
Ontario, Canada

Syed A. Hoda, MD
Professor of Pathology
Weill Medical College of Cornell University
Attending Pathologist
New York-Presbyterian Hospital
New York, NY

Claudine Isaacs, MD
Medical Director, Fisher Center for Familial Cancer Research
Co-Director, Breast Cancer Program
Georgetown University
Washington, DC

Henry Kuerer, MD, PhD, FACS
Professor of Surgery and Director, Breast Surgical Oncology Training Program
Medical Director, Clinical Expansion, MD Anderson Cancer Network
University of Texas MD Anderson Cancer Center
Houston, TX

Charles Loprinzi, MD
Regis Professor of Breast Cancer Research
Mayo Clinic
Rochester, MN

Anne McTiernan, MD, PhD
Research Professor, Epidemiology
Fred Hutchinson Cancer Research Center
Seattle, WA

Ruth O'Regan, MD
Chief, Division of Hematology/Oncology
University of Wisconsin
Carbone Cancer Center
Madison, WI

Soonmyung Paik, MD
National Surgical Adjuvant Breast and Bowel Project
Division of Pathology
Pittsburgh, PA

Elizabeth Rafferty, MD
Staff Radiologist
Avon Comprehensive Breast Center
Massachusetts General Hospital
Boston, MA

Edward H. Romond, MD
Professor of Medicine
Division of Medical Oncology
Markey Cancer Center
University of Kentucky
Lexington, KY

Hani Sbitany, MD
Assistant Professor of Surgery
Division of Plastic and Reconstructive Surgery
University of California, San Francisco
San Francisco, CA

David M. Schuster, MD
Associate Professor
Director, Division of Nuclear Medicine and Molecular Imaging
Department of Radiology and Imaging Sciences
Emory University Hospital
Atlanta, GA

Lawrence J. Solin, MD, FACR, FASTRO
Chairman, Department of Radiation Oncology
Albert Einstein Healthcare Network
Philadelphia, PA

Joseph Sparano, MD
Professor of Medicine
Professor of Obstetrics, Gynecology, and Women’s Health
Albert Einstein College of Medicine
Associate Chairman
Department of Oncology
Montefiore Medical Center
Bronx, NY

Catherine Van Poznak, MD
Associate Professor
Division of Hematology Oncology
Department of Internal Medicine
University of Michigan
Ann Arbor, MI

Jeffrey N. Weitzel, MD
Professor of Oncology and Population Sciences
Chief, Division of Clinical Cancer Genetics
City of Hope Cancer Center
Duarte, CA

Suzanna M. Zick, ND, MPH
Research Associate
Professor of Family Medicine
University of Michigan Medical School and Nutritional Sciences, School of Public Health
Ann Arbor, MI

Faculty, Staff, and Planners' Disclosures

The following individuals have no relevant financial relationships with commercial interests to disclose:

David Euhus, MD, FACS; Carol Fabian, MD; William J. Gradishar, MD, FASCO, FACP; Karin Hahn, MD, MSc, MPH; Syed A. Hoda, MD; Frankie Ann Holmes, MD, FACP; Anne McTiernan, MD, PhD; Anne Moore, MD; Soonmyung Paik, MD; David M. Schuster, MD; Lawrence J. Solin, MD, FACR, FASTRO; Jeffrey N. Weitzel, MD; Suzanna Zick, ND, MPH

The staff of Physicians’ Education Resource®, LLC.

The following individuals have relevant financial relationships with commercial interests to disclose:

Carey K. Anders, MD  – Consultant: Novartis, Sanofi, to-BBB Therapeutics, Geron, AngioChem, Merrimack Pharmaceuticals, Lilly, Genentech, Nektar Therapeutics, Kadmon Corporation; Research Funding: Novartis, Sanofi, to-BBB Therapeutics, Geron, AngioChem, Merrimack Pharmaceuticals, Puma Biotechnology, Lilly, Kadmon Corporation – all uncompensated; Douglas W. Arthur, MD  – Consultant: ImpediMed, Advanced Radiation Therapy; Claudine Isaacs, MD  – Grant/ Research Support: Novartis; Speaker’s Bureau: Genentech, Celgene Corporation; Henry M. Kuerer, MD, PhD, FACS – Grant/ Research Support: Genomic Health; Consultant: Gerson Lehrman Group, Lightpoint Medical, Inc.; Other: McGraw-Hill Publishing;  Charles Loprinzi, MD – Grant/Research Support: Bristol-Myers Squibb, Pfizer, Janssen; Consultant: Cubist Pharmaceuticals, Mitsubishi Tanabe Pharma, PledPharma; Eleftherios Mamounas, MD, MPH, FACS – Consultant: Genomic Health, Celgene Corporation, Pfizer, Novartis; Speaker’s Bureau: Genomic Health, Roche/ Genentech; Ruth O’Regan, MD – Consultant: Genentech, Pfizer, AstraZeneca; Joyce O’Shaughnessy, MD – Advisory Board/ Consultant: Arno Therapeutics, Celgene Corporation, Corcept Therapeutics, Eisai, Genentech, GlaxoSmithKline, Johnson & Johnson, Lilly, med fusion, Merrimack Pharmaceuticals, Millennium: The Takeda Oncology Company, Novartis, Pfizer, sanofi-aventis; Lori J. Pierce, MD, FASTRO – Shareholder: PFS Genomics (founder's shares); Elizabeth Rafferty, MD – Grant/Research Support: Principal Investigator, Research Grant from Hologic, Inc. for investigation of breast tomosynthesis; Edward H. Romond, MD – Grant/ Research Support: Genentech/ Roche; Hope S. Rugo, MD – Speakers Bureau: Genomic Health; Grant/Research Support: Amgen Inc., Eisai, Genentech, GlaxoSmithKline, Lilly, MacroGenics, Inc., Merck & Co., Inc., Novartis, OBI Pharma, Inc., Pfizer, Plexxikon Inc., Roche; Hani Sbitany, MD – Speaker’s Bureau: LifeCell; Joseph Sparano, MD – AstraZeneca, Novartis, Celgene Corporation, Genentech/Roche, Lilly, Celldex Therapeutics; Catherine Van Poznak, MD – Grant/Research Support: Bayer

Disclosure Policy and Resolution of Conflicts of Interest (COI)

It is the policy of PER® to ensure the fair balance, independence, objectivity, and scientific objectivity in all of our CME activities. In accordance with ACCME guidelines, PER® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest to participants as part of the activity planning process. PER® has implemented mechanisms to identify and resolve all conflicts of interest prior to release of this activity.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient's medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians' Education Resource®, LLC, or any of the companies that provided commercial support for this activity.

Hardware And Software Requirements

Supported Browsers
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)

Minimum System Requirements (Windows)
  • A Pentium-based PC or compatible computer
  • At least 64MB of RAM
  • Windows 95/98/NT/ME/2000/XP/Vista system software
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise
Minimum System Requirements (Mac OS)
  • A PowerPC processor-based Macintosh computer
  • At least 64MB of RAM
  • Mac OS 7.5 or later
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise

Calendar of Events
Filter By